Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.
Metadata
Item Type: | Proceedings Paper |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2023 The American Society of Hematology. Published by Elsevier. Reproduced in accordance with the publisher's self-archiving policy. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
Funding Information: | Funder Grant number Cancer Research UK Supplier No: 138573 CTUQQR-Dec22/100002 |
Depositing User: | Symplectic Publications |
Date Deposited: | 15 Mar 2024 12:04 |
Last Modified: | 02 Nov 2024 01:13 |
Status: | Published |
Publisher: | American Society of Hematology |
Identification Number: | 10.1182/blood-2023-187943 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:210276 |